Eko has secured $20 million in Series B funding. Led by ARTIS Ventures, according to a press release, the funding will drive further research and development and commercialisation of Eko’s machine learning platform for cardiac screening and analysis. Additional new and returning investors in the round include DigiTx Partners, NTT Venture Capital (NTTVC), 3M Ventures, Mayo Clinic, Seraph Group, and XTX Ventures.

Eko is collaborating with medical device and pharmaceutical companies to create combinations of therapies and data to help personalise cardiac care. The company will also grow its focus on clinical research, investing more in its collaborations with the Mayo Clinic, Northwestern Medicine, and UCSF. The press release states that expanding Eko’s collaborative studies will enable the company to build algorithms with more robust datasets targeted to specific conditions, including atrial fibrillation and valvular heart disease, as well as congestive heart failure and structural heart disease.

Connor Landgraf, CEO of Eko, comments: “With the staggering number of people affected by heart disease, it is clear that advancements in cardiac screening and monitoring have never been more urgent. Artificial intelligence is arguably one of the most powerful advancements in modern medicine, enabling clinicians to predict with more accuracy, diagnose with more confidence, and in the end, give their patients the best care possible. We will use this funding to drive more research, and continue development of data-driven technology to help physicians detect and monitor patients with heart disease that may otherwise be missed.”

Eko has developed the first cardiac monitor to combine digital stethoscope and ECG technology both for in-clinic and at-home monitoring, which enables patients to seamlessly and consistently send cardiac data to their physicians. Its platform is used by tens of thousands of clinicians treating millions of patients at over 3,000 hospitals and providers around the world.